We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Aspiration Cytology Is a Resource for Molecular Profiling

By LabMedica International staff writers
Posted on 23 Nov 2010
Archived and stained fine needle aspirate smears can be used for clinical molecular diagnosis and profiling. More...


DNA can be extracted from aspirate smears stained with Papanicolau (Pap) and Diff-Quick (DQ) stains that were prepared by technicians in a single laboratory according to standard procedure, mounted with a glass coverslips, and stored at room temperature under typical pathology archive conditions.

In a study performed at the National Cancer Institute, (Bethesda, MD, USA), 57 fine-needle aspiration cytopathology (FNAC) samples were examined for aberration detection on high-resolution comparative genomic hybridization array, DNA methylation, and single nucleotide polymorphism genotyping platforms. The samples were from patients with suspected small cell lung cancer (SCLC), metastatic lymph node cancer, and/or primary lymphoma.

Cellular material is collected by scraping the entire slide with a razor blade; this is facilitated by wetting the slide with a small amount of about 20 µL of lysis buffer, which helps the material form a clump during scraping. The average DNA yield per slide in this study was 7.4 µg (range: 0.1 µg to 27.9 µg). Unequivocal genomic structural aberrations were identified in 44 of 46 malignant smears. Even the degraded archival Pap smear DNA showed similar structural aberrations matched to DQ samples on Agilent array comparative genomic hybridization (Agilent; Santa Clara, CA, USA) and Infinium genotyping (Illumina; San Diego, CA, USA), although with greater background noise.

The authors of the study concluded, "Cytopathology specimens are an excellent potential source of patient materials for clinical molecular profiling, including retrospective genomic analyses and prospective sample collection for individualized therapy or eligibility review for clinical trial enrollment. FNAC samples up to 16 years old yielded copious quantities of genomic DNA suitable for high-resolution genomic and epigenomic profiling". The study was published in November 2010, in the Journal of Molecular Diagnostics.

Related Links:

National Cancer Institute
Agilent
Illumina



Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
8-Channel Pipette
SAPPHIRE 20–300 µL
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Original illustration showing how exposure-linked mutation patterns may influence tumor immune visibility (Photo courtesy of Máté Manczinger, HUN-REN Szeged BRC)

Cancer Mutation ‘Fingerprints’ to Improve Prediction of Immunotherapy Response

Cancer cells accumulate thousands of genetic mutations, but not all mutations affect tumors in the same way. Some make cancer cells more visible to the immune system, while others allow tumors to evade... Read more

Industry

view channel
Image: MG Tech adds STOMmics Stereo-seq spatial multi-omics technology to its potfolio (photo courtesy of STOmics)

MGI Tech Strengthens Sequencing Portfolio with Dual Acquisition

MGI Tech Co., Ltd. (Shenzhen, China) announced the acquisition of STOmics and CycloneSEQ on March 3, 2026, as part of its “SEQALL+GLI+Omics” strategy. According to the company, the combined portfolio spans... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.